DIDO1 Antibody

What is DIDO1 and what are its primary cellular functions?

DIDO1 (Death Inducer-Obliterator 1) is a putative transcription factor that exhibits weakly pro-apoptotic properties when overexpressed and functions as a tumor suppressor. The protein is initially cytoplasmic but translocates to the nucleus upon apoptotic signal activation . Recent research has revealed that DIDO1 plays essential roles beyond apoptosis, including:

• Regulating embryonic stem cell maintenance and pluripotency

• Acting as a target of canonical transcription factors including Oct4, Sox2, and Nanog

• Contributing to chromosome stability as a component of centrosome proteins

• Participating in spindle assembly during cell division

DIDO1 directly regulates the expression of pluripotency factors, creating a feedback loop where it occupies the loci of key pluripotency markers and positively regulates their expression. This mechanism appears critical for maintaining the self-renewal capabilities of stem cells .

What applications are DIDO1 antibodies most commonly used for?

DIDO1 antibodies are employed across multiple experimental applications in research settings. Based on validated protocols, the primary applications include:

These applications allow researchers to investigate DIDO1 expression patterns, localization changes during cellular processes, and protein-protein interactions in various experimental systems .

What is the molecular weight range for detecting DIDO1 in western blot analyses?

When detecting DIDO1 using western blot analysis, researchers should note a significant discrepancy between the calculated and observed molecular weights. While the calculated molecular weight of DIDO1 is approximately 59 kDa, the observed molecular weight on western blots typically appears between 300-350 kDa . This substantial difference may be attributed to:

• Post-translational modifications

• Protein oligomerization

• Highly charged regions affecting migration patterns

• Alternative splicing resulting in larger isoforms

Researchers should be aware of this discrepancy when interpreting western blot results and should use appropriate molecular weight markers spanning this range to accurately identify the DIDO1 protein band.

How does DIDO1 participate in the embryonic stem cell pluripotency network?

DIDO1 functions as an integral component of the embryonic stem cell (ESC) pluripotency regulatory network through multiple mechanisms:

• DIDO1 is directly targeted and regulated by master transcription factors including Nanog and Oct4, as demonstrated by ChIP assays showing enrichment of both factors on the DIDO1 promoter region (highest enrichment approximately 7 kb upstream of the transcriptional start site) .

• DIDO1 creates a regulatory feedback loop by directly binding to the promoter regions of pluripotency genes, including Nanog, Oct4, Sall4, and Sox2, thereby positively regulating their expression .

• In knockdown experiments, depletion of DIDO1 leads to:

  • Weaker alkaline phosphatase (AP) staining

  • Increased proportion of differentiated colonies

  • De-repression of lineage markers such as Cdx2 and Brachyury

  • Reduced levels of Oct4, Nanog, and Sox2 proteins

• Conversely, DIDO1 overexpression results in elevated expression of pluripotency markers at both mRNA and protein levels, even in the absence of LIF, although to a lesser degree compared to cells maintained with LIF .

This evidence establishes DIDO1 as a critical player in maintaining stem cell pluripotency through a complex feedforward and feedback regulatory mechanism.

What is the relationship between BAP1 and DIDO1 in chromosome stability maintenance?

The interaction between BAP1 (BRCA1-Associated Protein 1) and DIDO1 represents a critical mechanism for maintaining chromosome stability:

• BAP1 directly interacts with DIDO1 as confirmed by tandem affinity purification and co-immunoprecipitation experiments .

• BAP1 functions as a deubiquitinating enzyme that stabilizes DIDO1 through deubiquitination, preventing its degradation via the ubiquitin-proteasome pathway .

• DIDO1 acts as a component of centrosome proteins and plays an essential role in spindle assembly during cell division .

• The BAP1-DIDO1 axis contributes to chromosome stability, with disruption of this pathway potentially leading to chromosomal instability .

• In clear cell renal cell carcinoma (ccRCC), a positive correlation exists between BAP1 and DIDO1 expression, with downregulation of both proteins associated with adverse clinicopathological features .

This relationship highlights a novel regulatory mechanism where BAP1 maintains genomic integrity partially through stabilization of DIDO1, establishing a connection between BAP1 mutations and chromosome instability in cancer.

What are the optimal sample preparation methods for detecting DIDO1 in different cellular compartments?

DIDO1 exhibits dynamic subcellular localization, translocating from the cytoplasm to the nucleus upon apoptotic signal activation. For optimal detection in different cellular compartments, researchers should consider the following preparation methods:

For Nuclear Fraction:

• Use nuclear extraction buffers containing 10-20 mM HEPES (pH 7.9), 420 mM NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, and 25% glycerol

• Include protease inhibitors and phosphatase inhibitors to prevent degradation

• For immunofluorescence, fix cells with 4% paraformaldehyde and permeabilize with 0.1% Triton X-100

For Cytoplasmic Fraction:

• Use gentle lysis buffers (e.g., 10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA)

• Avoid detergents that might disrupt nuclear membranes

• For immunofluorescence, consider mild detergents like 0.05% saponin for selective cytoplasmic permeabilization

For Western Blot Detection:

• Load appropriate positive controls (e.g., Raji cells have been validated for DIDO1 detection)

• Use gradient gels (4-12%) to accommodate the large observed molecular weight (300-350 kDa)

• Extend transfer times (up to 16 hours at low voltage) to ensure complete transfer of high molecular weight proteins

How should researchers optimize immunohistochemical detection of DIDO1 in tissue samples?

For optimal immunohistochemical detection of DIDO1 in tissue samples, researchers should implement the following protocol:

• Antigen Retrieval:

  • Primary recommendation: Use TE buffer at pH 9.0

  • Alternative method: Citrate buffer at pH 6.0 may be used if TE buffer yields suboptimal results

  • Heat-induced epitope retrieval (HIER) for 20 minutes at 95-100°C

• Blocking and Antibody Parameters:

  • Block with 5-10% normal serum from the same species as the secondary antibody

  • Optimize primary antibody dilution within the range of 1:50-1:500

  • Incubate at 4°C overnight for maximum sensitivity

  • Use human breast cancer tissue as a positive control

• Detection Systems:

  • For brightfield microscopy: Use polymer-based detection systems rather than ABC methods

  • For fluorescence: Select secondary antibodies with minimal cross-reactivity to the species being examined

• Counterstaining Considerations:

  • Use light hematoxylin counterstaining to avoid masking weak DIDO1 signals

  • For fluorescence, DAPI nuclear counterstain helps identify nuclear translocation of DIDO1

• Controls:

  • Include internal positive controls where possible

  • Implement antibody validation through peptide competition assays

This optimized protocol accounts for the specific characteristics of DIDO1 antibodies and provides a framework for consistent, reproducible immunohistochemical detection.

How can researchers address discrepancies between calculated and observed molecular weights of DIDO1?

The significant discrepancy between the calculated (59 kDa) and observed (300-350 kDa) molecular weights of DIDO1 can pose challenges for data interpretation. Researchers can address this issue through several approaches:

• Validation through multiple detection methods:

  • Confirm DIDO1 identity using multiple antibodies targeting different epitopes

  • Perform immunoprecipitation followed by mass spectrometry for definitive identification

  • Use DIDO1 overexpression and knockdown controls to verify band identity

• Investigation of potential causes:

  • Assess post-translational modifications using phosphatase or glycosidase treatments

  • Analyze potential protein-protein interactions through crosslinking experiments

  • Examine alternative splicing through RT-PCR with isoform-specific primers

• Optimization of electrophoresis conditions:

  • Use lower percentage gels (3-8% gradient) for better resolution of high molecular weight proteins

  • Include reducing agents to eliminate potential disulfide bonding

  • Vary sample preparation conditions (heating time, detergent concentration) to assess aggregation effects

• Data reporting standards:

  • Clearly document both calculated and observed molecular weights in publications

  • Include validation experiments in supplementary data

  • Reference previous literature reporting similar molecular weight discrepancies

What considerations should be made when interpreting DIDO1 expression in the context of pluripotency studies?

When interpreting DIDO1 expression data in pluripotency studies, researchers should consider several key factors:

• Relationship with master pluripotency factors:

  • DIDO1 expression is regulated by Oct4, Sox2, and Nanog, creating a complex regulatory network

  • Changes in DIDO1 expression may be secondary to alterations in these master regulators

  • ChIP data indicates reciprocal binding between DIDO1 and pluripotency factors, forming regulatory feedback loops

• Functional validation requirements:

  • Simple correlation with pluripotency markers is insufficient to establish causality

  • Genetic rescue experiments using siRNA-resistant constructs provide stronger evidence of DIDO1's role

  • Assessed through multiple readouts including AP staining, morphology changes, and lineage marker expression

• Temporal dynamics considerations:

  • DIDO1's role may vary during different stages of pluripotency or differentiation

  • Time-course analyses are more informative than single timepoint measurements

  • Different culture conditions (with or without LIF) affect the magnitude of DIDO1's influence on pluripotency markers

• Technical limitations to acknowledge:

  • Antibody specificity must be validated in the experimental system

  • DIDO1 isoforms may have distinct functions in pluripotency maintenance

  • Background genetic differences between cell lines may influence interpretation

By addressing these considerations, researchers can more accurately interpret the complex relationship between DIDO1 expression and stemness, avoiding oversimplification of its role in the pluripotency network.

What are the recommended approaches for studying DIDO1 in chromatin regulation and genomic stability?

DIDO1's involvement in chromatin regulation and genomic stability necessitates specialized methodological approaches:

• Chromatin Immunoprecipitation (ChIP) Strategies:

  • Target regions approximately 7 kb upstream of the DIDO1 transcriptional start site when studying regulation by pluripotency factors

  • For DIDO1 binding studies, examine promoter regions of pluripotency genes including Nanog, Oct4, Sall4, and Sox2

  • Implement ChIP-seq to identify genome-wide binding patterns and potential consensus motifs

  • Utilize sequential ChIP (re-ChIP) to analyze co-occupancy with other transcription factors

• Genomic Stability Assessment Methods:

  • Monitor chromosome segregation using live-cell imaging with fluorescently labeled histones

  • Quantify micronuclei formation as an indicator of chromosomal instability

  • Implement metaphase spread analysis to detect structural chromosomal abnormalities

  • Assess spindle assembly defects through immunofluorescence of mitotic markers

• BAP1-DIDO1 Interaction Studies:

  • Employ proximity ligation assays to visualize interactions in situ

  • Utilize FRET-based approaches to analyze dynamic interaction patterns

  • Design domain-specific mutations to map critical interaction interfaces

  • Implement deubiquitination assays to assess functional consequences of the interaction

• Integrative Analysis Approaches:

  • Correlate chromatin binding patterns with transcriptome changes

  • Integrate epigenetic modification data (e.g., histone marks) with DIDO1 binding profiles

  • Assess chromosome stability parameters in conjunction with DIDO1/BAP1 expression levels

  • Implement CRISPR-based genomic editing to introduce specific mutations for functional studies

These methodological approaches provide a comprehensive framework for investigating DIDO1's multifaceted roles in chromatin regulation and genomic stability maintenance.

What experimental systems are optimal for studying the role of DIDO1 in stem cell biology?

When investigating DIDO1's functions in stem cell biology, selecting appropriate experimental systems is crucial for obtaining meaningful results:

• Cellular Models:

  • Mouse embryonic stem cells (mESCs): Widely validated system with established pluripotency markers and differentiation protocols; successfully used in previous DIDO1 studies

  • Human embryonic stem cells (hESCs): Provide translational relevance but may exhibit species-specific regulatory differences

  • Induced pluripotent stem cells (iPSCs): Allow for studying DIDO1 during reprogramming process

  • Tissue-specific stem cells: Enable exploration of DIDO1's role in adult stem cell maintenance

• Genetic Manipulation Approaches:

  • Transient knockdown: Use validated siRNAs targeting DIDO1 with demonstrated ~70-80% knockdown efficiency

  • Stable knockdown: Implement inducible shRNA systems for temporal control of DIDO1 depletion

  • Overexpression studies: Utilize retroviral vectors under EF1α promoter control with appropriate tags (HA, FLAG) for detection

  • Rescue experiments: Express siRNA-resistant constructs to confirm specificity of observed phenotypes

• Differentiation Paradigms:

  • Embryoid body formation: Assess DIDO1's impact on spontaneous differentiation

  • Directed differentiation: Examine lineage-specific effects using established protocols

  • Teratoma formation assays: Evaluate pluripotency in vivo

  • Colony formation assays with alkaline phosphatase staining: Quantify self-renewal capacity

• Readout Systems:

  • Transcriptional profiling: RNA-seq to capture global changes in gene expression

  • Protein analysis: Western blotting for key pluripotency factors (Nanog, Oct4, Sox2)

  • Epigenetic assessment: ChIP-seq for histone modifications associated with active/repressed chromatin

  • Functional assays: Colony morphology, differentiation marker expression, and cell cycle analysis

By integrating these experimental systems and approaches, researchers can comprehensively characterize DIDO1's regulatory mechanisms and functional significance in stem cell biology.

How might DIDO1 function as a therapeutic target in cancer research?

The emerging understanding of DIDO1's roles in chromosome stability, apoptosis, and stem cell maintenance suggests several potential therapeutic applications in cancer research:

• DIDO1 in Tumor Suppression Pathways:

  • DIDO1 functions as a tumor suppressor, with its expression correlating with favorable clinical outcomes in certain cancers

  • The BAP1-DIDO1 axis maintains chromosome stability, and disruption of this pathway may contribute to tumorigenesis

  • Therapeutic strategies could focus on restoring DIDO1 expression or function in cancers where it is downregulated

• DIDO1 and Genomic Instability:

  • DIDO1's role in centrosome function and spindle assembly suggests it may influence sensitivity to anti-mitotic therapies

  • Targeting cancers with DIDO1 deficiency using compounds that exacerbate mitotic stress could provide synthetic lethality approaches

  • Combinatorial approaches with existing chromosomal instability (CIN)-targeting drugs may enhance therapeutic efficacy

• DIDO1 in Renal Cell Carcinoma:

  • Positive correlation between BAP1 and DIDO1 expression in ccRCC tissues suggests diagnostic and prognostic applications

  • Downregulation of both BAP1 and DIDO1 protein expression is associated with adverse clinicopathological features

  • Monitoring DIDO1 expression may help stratify patients for targeted therapies, particularly those targeting the ubiquitin-proteasome system

• Methodological Research Directions:

  • Develop high-throughput screening assays to identify compounds that modulate DIDO1 stability or function

  • Investigate pharmacological approaches to enhance BAP1-mediated stabilization of DIDO1

  • Explore synthetic lethality approaches in tumors with compromised DIDO1 function

These research directions represent promising avenues for translating basic understanding of DIDO1 biology into therapeutic applications for cancer treatment.